File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cancers12082142
- Scopus: eid_2-s2.0-85090516388
- PMID: 32748879
- WOS: WOS:000578907500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lytic induction therapy against Epstein-Barr Virus-Associated malignancies: past, present, and future
Title | Lytic induction therapy against Epstein-Barr Virus-Associated malignancies: past, present, and future |
---|---|
Authors | |
Keywords | Epstein–Barr virus lytic induction therapy endemic Burkitt lymphoma Hodgkin lymphoma T-/NK-/B-cell non-Hodgkin lymphoma |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/ |
Citation | Cancers, 2020, v. 12 n. 8, p. article no. 2142 How to Cite? |
Abstract | Epstein–Barr virus (EBV) lytic induction therapy is an emerging virus-targeted therapeutic approach that exploits the presence of EBV in tumor cells to confer specific killing effects against EBV-associated malignancies. Efforts have been made in the past years to uncover the mechanisms of EBV latent-lytic switch and discover different classes of chemical compounds that can reactivate the EBV lytic cycle. Despite the growing list of compounds showing potential to be used in the lytic induction therapy, only a few are being tested in clinical trials, with varying degrees of success. This review will summarize the current knowledge on EBV lytic reactivation, the major hurdles of translating the lytic induction therapy into clinical settings, and highlight some potential strategies in the future development of this therapy for EBV-related lymphoid and epithelial malignancies. |
Persistent Identifier | http://hdl.handle.net/10722/289155 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.391 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yiu, SPT | - |
dc.contributor.author | DOROTHEA, M | - |
dc.contributor.author | Hui, KF | - |
dc.contributor.author | Chiang, AKS | - |
dc.date.accessioned | 2020-10-22T08:08:36Z | - |
dc.date.available | 2020-10-22T08:08:36Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Cancers, 2020, v. 12 n. 8, p. article no. 2142 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/10722/289155 | - |
dc.description.abstract | Epstein–Barr virus (EBV) lytic induction therapy is an emerging virus-targeted therapeutic approach that exploits the presence of EBV in tumor cells to confer specific killing effects against EBV-associated malignancies. Efforts have been made in the past years to uncover the mechanisms of EBV latent-lytic switch and discover different classes of chemical compounds that can reactivate the EBV lytic cycle. Despite the growing list of compounds showing potential to be used in the lytic induction therapy, only a few are being tested in clinical trials, with varying degrees of success. This review will summarize the current knowledge on EBV lytic reactivation, the major hurdles of translating the lytic induction therapy into clinical settings, and highlight some potential strategies in the future development of this therapy for EBV-related lymphoid and epithelial malignancies. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/ | - |
dc.relation.ispartof | Cancers | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Epstein–Barr virus | - |
dc.subject | lytic induction therapy | - |
dc.subject | endemic Burkitt lymphoma | - |
dc.subject | Hodgkin lymphoma | - |
dc.subject | T-/NK-/B-cell non-Hodgkin lymphoma | - |
dc.title | Lytic induction therapy against Epstein-Barr Virus-Associated malignancies: past, present, and future | - |
dc.type | Article | - |
dc.identifier.email | Chiang, AKS: chiangak@hku.hk | - |
dc.identifier.authority | Chiang, AKS=rp00403 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/cancers12082142 | - |
dc.identifier.pmid | 32748879 | - |
dc.identifier.pmcid | PMC7465660 | - |
dc.identifier.scopus | eid_2-s2.0-85090516388 | - |
dc.identifier.hkuros | 317441 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | article no. 2142 | - |
dc.identifier.epage | article no. 2142 | - |
dc.identifier.isi | WOS:000578907500001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2072-6694 | - |